aTyr Pharma, Inc. (ATYR) - Net Assets
Based on the latest financial reports, aTyr Pharma, Inc. (ATYR) has net assets worth $67.29 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($94.16 Million) and total liabilities ($26.88 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check aTyr Pharma, Inc. (ATYR) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $67.29 Million |
| % of Total Assets | 71.46% |
| Annual Growth Rate | N/A |
| 5-Year Change | -38.34% |
| 10-Year Change | 7.14% |
| Growth Volatility | 83.49 |
aTyr Pharma, Inc. - Net Assets Trend (2012–2025)
This chart illustrates how aTyr Pharma, Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore ATYR total assets for the complete picture of this company's asset base.
Annual Net Assets for aTyr Pharma, Inc. (2012–2025)
The table below shows the annual net assets of aTyr Pharma, Inc. from 2012 to 2025. For live valuation and market cap data, see how much is aTyr Pharma, Inc. worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $67.29 Million | -3.64% |
| 2024-12-31 | $69.83 Million | -22.81% |
| 2023-12-31 | $90.47 Million | +26.91% |
| 2022-12-31 | $71.28 Million | -34.68% |
| 2021-12-31 | $109.13 Million | +246.61% |
| 2020-12-31 | $31.48 Million | +49.74% |
| 2019-12-31 | $21.03 Million | -37.52% |
| 2018-12-31 | $33.65 Million | -47.62% |
| 2017-12-31 | $64.25 Million | +2.30% |
| 2016-12-31 | $62.80 Million | -45.41% |
| 2015-12-31 | $115.05 Million | +226.41% |
| 2014-12-31 | $-91.01 Million | -37.72% |
| 2013-12-31 | $-66.08 Million | -5144.60% |
| 2012-12-31 | $-1.26 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to aTyr Pharma, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 54164800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $98.00K | 0.15% |
| Other Comprehensive Income | $-8.00K | -0.01% |
| Other Components | $673.55 Million | 998.15% |
| Total Equity | $67.48 Million | 100.00% |
aTyr Pharma, Inc. Competitors by Market Cap
The table below lists competitors of aTyr Pharma, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jaya Konstruksi Manggala Pratama
JK:JKON
|
$73.58 Million |
|
Solutions 30 SE
F:30L3
|
$73.59 Million |
|
Tex Cycle Technology M Bhd
KLSE:0089
|
$73.61 Million |
|
Kestrel Group, Ltd.
NASDAQ:KG
|
$73.63 Million |
|
Satia Industries Limited
NSE:SATIA
|
$73.51 Million |
|
Taiwan Allied Container Terminal
TWO:5601
|
$73.50 Million |
|
Cape EMS Berhad
KLSE:5311
|
$73.47 Million |
|
Polygon-L
TA:POLY
|
$73.46 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in aTyr Pharma, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 70,019,000 to 67,480,000, a change of -2,539,000 (-3.6%).
- Net loss of 74,118,000 reduced equity.
- New share issuances of 66,423,000 increased equity.
- Other comprehensive income increased equity by 32,000.
- Other factors increased equity by 5,124,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-74.12 Million | -109.84% |
| Share Issuances | $66.42 Million | +98.43% |
| Other Comprehensive Income | $32.00K | +0.05% |
| Other Changes | $5.12 Million | +7.59% |
| Total Change | $- | -3.63% |
Book Value vs Market Value Analysis
This analysis compares aTyr Pharma, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.15x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-0.03 | $0.83 | x |
| 2013-12-31 | $-1257.20 | $0.83 | x |
| 2014-12-31 | $-1527.35 | $0.83 | x |
| 2015-12-31 | $101.70 | $0.83 | x |
| 2016-12-31 | $37.13 | $0.83 | x |
| 2017-12-31 | $34.86 | $0.83 | x |
| 2018-12-31 | $15.73 | $0.83 | x |
| 2019-12-31 | $6.31 | $0.83 | x |
| 2020-12-31 | $3.46 | $0.83 | x |
| 2021-12-31 | $5.73 | $0.83 | x |
| 2022-12-31 | $2.51 | $0.83 | x |
| 2023-12-31 | $1.69 | $0.83 | x |
| 2024-12-31 | $0.94 | $0.83 | x |
| 2025-12-31 | $0.73 | $0.83 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently aTyr Pharma, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -109.84%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -39009.47%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.40x
- Recent ROE (-109.84%) is below the historical average (-58.95%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.48 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.16 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.25 Million |
| 2015 | -41.70% | 0.00% | 0.00x | 1.13x | $-59.48 Million |
| 2016 | -92.12% | 0.00% | 0.00x | 1.28x | $-64.14 Million |
| 2017 | -75.04% | 0.00% | 0.00x | 1.39x | $-54.63 Million |
| 2018 | -102.57% | 0.00% | 0.00x | 1.57x | $-37.88 Million |
| 2019 | -111.41% | -5593.13% | 0.01x | 1.71x | $-25.72 Million |
| 2020 | -51.26% | -155.18% | 0.27x | 1.22x | $-19.39 Million |
| 2021 | -30.89% | 0.00% | 0.00x | 1.06x | $-44.70 Million |
| 2022 | -63.44% | -436.53% | 0.11x | 1.34x | $-52.48 Million |
| 2023 | -55.58% | -14274.50% | 0.00x | 1.33x | $-59.45 Million |
| 2024 | -91.44% | -27243.83% | 0.00x | 1.38x | $-71.02 Million |
| 2025 | -109.84% | -39009.47% | 0.00x | 1.40x | $-80.87 Million |
Industry Comparison
This section compares aTyr Pharma, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| aTyr Pharma, Inc. (ATYR) | $67.29 Million | 0.00% | 0.40x | $73.54 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About aTyr Pharma, Inc.
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinica… Read more